2011 - CTS-IXA


This page contains exclusive content for the member of the following sections: TTS, CTS, IXA. Log in to view.

Parallel Session 3- Genetic Engineering (Xeno Track)

5.120 - Islet-specific expression of TFPI, CD39, and CTLA4Ig in transgenic pigs designed for xenoislet transplantion

Presenter: David, Ayares, Blacksburg, United States
Authors: David Ayares1, Todd Vaught1, Suyapa Ball1, Jagdeece Ramsoondar1, Jeff Monahan1, Michael Mendicino1, Anneke Walters1, Amy Dandro1, Angelica Giraldo1, Suzanne Berterra2, Rita Bottino2, Massimo Trucco2, Carol Phelps1

120

Islet-specific expression of TFPI, CD39, and CTLA4Ig in transgenic pigs designed for xenoislet transplantation

David Ayares1, Todd Vaught1, Suyapa Ball1, Jagdeece Ramsoondar1, Jeff Monahan1, Michael Mendicino1, Anneke Walters1, Amy Dandro1, Angelica Giraldo1, Suzanne Berterra2, Rita Bottino2, Massimo Trucco2, Carol Phelps1

1Revivicor Inc, Blacksburg, Virginia, United States; 2Children’s Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Background: Pig islets with Gal-transferase knockout (GTKO) and/or constitutive expression of hCD46 have shown long-term function and successful restoration of insulin independence in nonhuman primate (NHP) models. An islet-specific expression system has been designed for expression of multiple immunomodulatory transgenes, for inhibition of thrombosis, inflammation, early islet loss, and rejection, towards improved xenoislet transplant outcomes.

Methods: Human CD39, human TFPI, and porcine CTLA4Ig transgenes were cloned individually into an islet-specific expression vector containing the rat insulin II promoter and mouse PDX-1 enhancer. All three vectors (CD39ins, TFPIins and CTLA4Igins) were transfected alone or co-transfected in combination into pig fibroblast cells which were already transgenic for hCD46 and homozygous GTKO. Southern (+) GTKO/hCD46/CD39ins, GTKO/hCD46/TFPIins/CTLA4Igins, and GTKO/hCD46/CD39ins/TFPIins/CTLA4Igins cell lines were used for nuclear transfer (NT) to produce pregnancies. Cloned fetuses were analyzed for expression in fetal organs (pancreas, heart, liver) by IHC, Western, and real-time PCR. Fetal fibroblasts with confirmed expression of the desired transgenes were used for NT to produce live pigs.

Results: Viable multi-transgenic pigs with three, four, or five different genetic modifications were produced. Three different pig lines were established: 1) GTKO/hCD46/CD39ins, 2) GTKO/hCD46/TFPIins/CTLA4Igins, and 3) GTKO/hCD46/CD39ins/TFPIins/CTLA4Igins. IHC revealed robust islet-specific expression of CD39, TFPI and CTLA4Ig in pancreas, with only background expression in heart and liver. Islets from pigs containing the TFPI transgene, when mixed with human blood, showed prolonged clotting times. Western analysis showed strong pCTLA4Ig expression only in the pancreas. To date, the three and four gene pig lines have been bred and produced viable offspring.

Conclusions: Building on GTKO/CD46 genetics, an islet-specific expression system was used to produce multi-transgenic pigs with CD39, TFPI, and CTLA4Ig to inhibit activation of tissue factor, inflammation, coagulopathy, and cellular rejection. Islets will be isolated from these pigs to evaluate efficacy in NHP models towards clinical application of xenoislet transplantation.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada